453 related articles for article (PubMed ID: 29623846)
1. Immune Mediated Necrotizing Myopathy: Where do we Stand?
Mohammed AGA; Gcelu A; Moosajee F; Botha S; Kalla AA
Curr Rheumatol Rev; 2019; 15(1):23-26. PubMed ID: 29623846
[TBL] [Abstract][Full Text] [Related]
2. Immune-Mediated Necrotizing Myopathy.
Pinal-Fernandez I; Casal-Dominguez M; Mammen AL
Curr Rheumatol Rep; 2018 Mar; 20(4):21. PubMed ID: 29582188
[TBL] [Abstract][Full Text] [Related]
3. Immune-mediated necrotizing myopathy (IMNM): A myopathological challenge.
Merlonghi G; Antonini G; Garibaldi M
Autoimmun Rev; 2022 Feb; 21(2):102993. PubMed ID: 34798316
[TBL] [Abstract][Full Text] [Related]
4. Peculiar clinicopathological features of immune-mediated necrotizing myopathies.
Allenbach Y; Benveniste O
Curr Opin Rheumatol; 2018 Nov; 30(6):655-663. PubMed ID: 30239349
[TBL] [Abstract][Full Text] [Related]
5. Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy.
Watanabe Y; Uruha A; Suzuki S; Nakahara J; Hamanaka K; Takayama K; Suzuki N; Nishino I
J Neurol Neurosurg Psychiatry; 2016 Oct; 87(10):1038-44. PubMed ID: 27147697
[TBL] [Abstract][Full Text] [Related]
6. Potential Pathogenic Role of Anti-Signal Recognition Protein and Anti-3-hydroxy-3-methylglutaryl-CoA Reductase Antibodies in Immune-Mediated Necrotizing Myopathies.
Ladislau L; Arouche-Delaperche L; Allenbach Y; Benveniste O
Curr Rheumatol Rep; 2018 Aug; 20(9):56. PubMed ID: 30074107
[TBL] [Abstract][Full Text] [Related]
7. Immune-mediated necrotizing myopathy: clinical features and pathogenesis.
Allenbach Y; Benveniste O; Stenzel W; Boyer O
Nat Rev Rheumatol; 2020 Dec; 16(12):689-701. PubMed ID: 33093664
[TBL] [Abstract][Full Text] [Related]
8. Spectrum of immune-mediated necrotizing myopathies and their treatments.
Pinal-Fernandez I; Mammen AL
Curr Opin Rheumatol; 2016 Nov; 28(6):619-24. PubMed ID: 27607340
[TBL] [Abstract][Full Text] [Related]
9. Immune-mediated myopathy related to anti 3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies as an emerging cause of necrotizing myopathy induced by statins.
Lahaye C; Beaufrére AM; Boyer O; Drouot L; Soubrier M; Tournadre A
Joint Bone Spine; 2014 Jan; 81(1):79-82. PubMed ID: 23953224
[TBL] [Abstract][Full Text] [Related]
10. [Immune-Mediated Necrotizing Myopathy].
Uruha A
Brain Nerve; 2024 May; 76(5):646-654. PubMed ID: 38741508
[TBL] [Abstract][Full Text] [Related]
11.
Bergua C; Chiavelli H; Allenbach Y; Arouche-Delaperche L; Arnoult C; Bourdenet G; Jean L; Zoubairi R; Guerout N; Mahler M; Benveniste O; Drouot L; Boyer O
Ann Rheum Dis; 2019 Jan; 78(1):131-139. PubMed ID: 30309969
[TBL] [Abstract][Full Text] [Related]
12. Perivascular and endomysial macrophages expressing VEGF and CXCL12 promote angiogenesis in anti-HMGCR immune-mediated necrotizing myopathy.
Lia A; Annese T; Fornaro M; Giannini M; D'Abbicco D; Errede M; Lorusso L; Amati A; Tampoia M; Trojano M; Virgintino D; Ribatti D; Serlenga L; Iannone F; Girolamo F
Rheumatology (Oxford); 2022 Aug; 61(8):3448-3460. PubMed ID: 34864921
[TBL] [Abstract][Full Text] [Related]
13. Immune-Mediated Necrotizing Myopathy: Update on Diagnosis and Management.
Basharat P; Christopher-Stine L
Curr Rheumatol Rep; 2015 Dec; 17(12):72. PubMed ID: 26515574
[TBL] [Abstract][Full Text] [Related]
14. Toll-like receptors and IL-7 as potential biomarkers for immune-mediated necrotizing myopathies.
Cappelletti C; Brugnoni R; Bonanno S; Andreetta F; Salerno F; Canioni E; Vattemi GNA; Tonin P; Mantegazza R; Maggi L
Eur J Immunol; 2023 Nov; 53(11):e2250326. PubMed ID: 37562045
[TBL] [Abstract][Full Text] [Related]
15. The pathogenesis of anti-signal recognition particle necrotizing myopathy: A Review.
Qiu R; Wang Z; Wei X; Sui H; Jiang Z; Yu XF
Biomed Pharmacother; 2022 Dec; 156():113936. PubMed ID: 36411623
[TBL] [Abstract][Full Text] [Related]
16. Immune-mediated necrotising myopathy: A critical review of current concepts.
Day JA; Limaye V
Semin Arthritis Rheum; 2019 Dec; 49(3):420-429. PubMed ID: 31109639
[TBL] [Abstract][Full Text] [Related]
17. [Clinical and pathological characteristics of immune mediated necrotizing myopathy].
Yang HX; Tian XL; Jiang W; Li WL; Liu QY; Peng QL; Wang GC; Lu X
Beijing Da Xue Xue Bao Yi Xue Ban; 2019 Dec; 51(6):989-995. PubMed ID: 31848492
[TBL] [Abstract][Full Text] [Related]
18. Clinical and histological features of immune-mediated necrotising myopathy: A multi-centre South Australian cohort study.
Day J; Otto S; Cash K; Limaye V
Neuromuscul Disord; 2020 Mar; 30(3):186-199. PubMed ID: 32229165
[TBL] [Abstract][Full Text] [Related]
19. [Retrospective study on clinical manifestation, thigh MRI and electrophysiology characteristics of immune-mediated necrotizing myopathy].
Qiao LY; Shi Q; Lin MY; Liu J; Chen ZJ; Pu C
Zhonghua Nei Ke Za Zhi; 2022 Oct; 61(10):1144-1151. PubMed ID: 36207969
[No Abstract] [Full Text] [Related]
20. Therapeutic management of immune-mediated necrotizing myositis.
Weeding E; Tiniakou E
Curr Treatm Opt Rheumatol; 2021 Jun; 7(2):150-160. PubMed ID: 34422547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
